Zoono Group Limited, together with its subsidiaries, engages in the research, development, and sale of a range of antimicrobial products worldwide. More Details
Flawless balance sheet and undervalued.
Share Price & News
How has Zoono Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ZNO is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ZNO's weekly volatility has decreased from 20% to 10% over the past year.
7 Day Return
1 Year Return
Return vs Industry: ZNO exceeded the Australian Chemicals industry which returned -24.3% over the past year.
Return vs Market: ZNO exceeded the Australian Market which returned 0.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Zoono Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StHow Should Investors React To Zoono Group's (ASX:ZNO) CEO Pay?
3 weeks ago | Simply Wall StZoono Group Limited's (ASX:ZNO) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
1 month ago | Simply Wall StHere's Why We Don't Think Zoono Group's (ASX:ZNO) Statutory Earnings Reflect Its Underlying Earnings Potential
Is Zoono Group undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ZNO (A$1.34) is trading below our estimate of fair value (A$2.96)
Significantly Below Fair Value: ZNO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ZNO is good value based on its PE Ratio (13.9x) compared to the AU Chemicals industry average (33.2x).
PE vs Market: ZNO is good value based on its PE Ratio (13.9x) compared to the Australian market (22.7x).
Price to Earnings Growth Ratio
PEG Ratio: ZNO is good value based on its PEG Ratio (0.8x)
Price to Book Ratio
PB vs Industry: ZNO is overvalued based on its PB Ratio (11x) compared to the AU Chemicals industry average (3.3x).
How is Zoono Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZNO's forecast earnings growth (17.3% per year) is above the savings rate (2.3%).
Earnings vs Market: ZNO's earnings (17.3% per year) are forecast to grow slower than the Australian market (18.5% per year).
High Growth Earnings: ZNO's earnings are forecast to grow, but not significantly.
Revenue vs Market: ZNO's revenue (17.5% per year) is forecast to grow faster than the Australian market (5.2% per year).
High Growth Revenue: ZNO's revenue (17.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZNO's Return on Equity is forecast to be very high in 3 years time (46.3%).
How has Zoono Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZNO has a high level of non-cash earnings.
Growing Profit Margin: ZNO became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: ZNO's earnings have grown significantly by 77% per year over the past 5 years.
Accelerating Growth: ZNO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ZNO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Chemicals industry (-4.2%).
Return on Equity
High ROE: ZNO's Return on Equity (79.5%) is considered outstanding.
How is Zoono Group's financial position?
Financial Position Analysis
Short Term Liabilities: ZNO's short term assets (NZ$32.9M) exceed its short term liabilities (NZ$12.4M).
Long Term Liabilities: ZNO's short term assets (NZ$32.9M) exceed its long term liabilities (NZ$1.4M).
Debt to Equity History and Analysis
Debt Level: ZNO is debt free.
Reducing Debt: ZNO had no debt 5 years ago.
Debt Coverage: ZNO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ZNO has no debt, therefore coverage of interest payments is not a concern.
What is Zoono Group current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ZNO's dividend (2.27%) is higher than the bottom 25% of dividend payers in the Australian market (2.07%).
High Dividend: ZNO's dividend (2.27%) is low compared to the top 25% of dividend payers in the Australian market (5%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether ZNO's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if ZNO's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (31.5%), ZNO's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ZNO's dividends in 3 years are forecast to be well covered by earnings (46.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Paul Hyslop has been the Managing Director and Director of Zoono Group Limited since April 26, 2017 and serves as its Chief Executive Officer. Mr. Hyslop's primary responsibility is to determine the st...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD301.49K) is below average for companies of similar size in the Australian market ($USD525.48K).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
|CEO, MD & Director||no data||NZ$427.94k||40.68% |
|Company Secretary & Independent Non-Executive Director||5.17yrs||NZ$65.23k||0.17% |
|Non-Executive Independent Director||3.67yrs||NZ$65.23k||0.17% |
Experienced Board: ZNO's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Zoono Group Limited's company bio, employee growth, exchange listings and data sources
- Name: Zoono Group Limited
- Ticker: ZNO
- Exchange: ASX
- Founded: 1986
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: AU$219.241m
- Shares outstanding: 163.61m
- Website: https://zoono.com
- Zoono Group Limited
- 24 Bishop Dunn Place
- Botany South
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ZNO||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||May 2017|
|ZNO||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||May 2017|
|ZNOG.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||May 2017|
Zoono Group Limited, together with its subsidiaries, engages in the research, development, and sale of a range of antimicrobial products worldwide. The company’s products include hand sanitizers, textile a...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/05 07:07|
|End of Day Share Price||2020/12/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.